Researchers at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have identified the IL1RAP receptor as a potential weak point in the inflammatory network of pancreatic tumors, potentially dismantling the dense, fibrous shield that allows the disease to evade treatment and suppress immune responses.
Understanding the Fibrotic Microenvironment
Pancreatic tumors present a formidable therapeutic challenge because they are not made up of cancer cells alone. Instead, they are surrounded by scar-like tissue, immune cells, and support cells. This surrounding cellular network can limit drug penetration while suppressing immune responses, helping cancer cells survive under stress.
When chemotherapy damages cancer cells, the surrounding cellular network can help the disease recover and adapt. This biology explains why treatments that work in other cancers often have limited effects in pancreatic tumors. Even though modern KRAS-directed medications have brought hope to those with metastatic cancer, extending those same breakthroughs to individuals with resectable pancreatic tumors could take years, highlighting the necessity for approaches capable of earlier evaluation prior to surgery.
IL1RAP as a Signaling Hub
To find a way past these defenses, Jashodeep Datta and his colleagues examined the role of IL1RAP, a receptor that helps transmit several inflammatory signals. Their findings were published in JCI Insight. The research reveals that IL1RAP acts as a link among cancer cells, immune cells, and fibroblasts—cells that help produce the structural tissue surrounding tumors.
These various cellular components form an interactive network that fuels cancer progression and reduces therapy effectiveness. “When we target IL1RAP, we are blocking a shared ‘helper’ receptor that many inflammatory signals rely on to transmit their message,” noted Datta, who serves as a pancreatic and hepatobiliary surgical oncologist and co-leader of the Gastrointestinal Site Disease Group at Sylvester.
Inhibiting this receptor can modulate multiple inflammatory cascades simultaneously because it occupies a central junction within the signaling architecture. This disruption addresses the “inflamed but immune-suppressed” environment characteristic of pancreatic tumors, where the tumor may contain many immune-related signals, yet the immune cells capable of attacking cancer remain weakened or restrained.
Dismantling the Tumor Support System
Preclinical experiments demonstrate that inhibiting IL1RAP changed the composition of the tumor microenvironment. Following inhibition, immune-suppressive cells became less abundant, while T cells showed stronger activity. Additionally, the tumors developed less fibrosis and responded better to combination therapy.
Rather than acting as a direct strike against cancer cells, IL1RAP-targeted treatment may work as a way to dismantle the support system around them. The aim is to make the tumor environment less protective so that existing therapies can work more effectively.
Preparing for Clinical Translation
These findings have prompted a planned clinical trial at Sylvester Comprehensive Cancer Center. A forthcoming clinical trial at Sylvester will evaluate patients whose cancers are still operable by pairing an IL1RAP-blocking agent with chemoimmunotherapy in the preoperative period.
